Title: Effectiveness of an Impella versus intra-aortic balloon pump in patients who received

2 extracorporeal membrane oxygenation

- 4 **Authors:** Yuji Nishimoto¹; Hiroyuki Ohbe²; Jun Nakata³; Toru Takiguchi⁴; Mikio Nakajima^{2,5};
- 5 Yusuke Sasabuchi⁶; Toshiaki Isogai^{2,7}; Hiroki Matsui²; Yukihito Sato⁸; Tetsuya Watanabe¹; Takahisa
- 6 Yamada¹; Masatake Fukunami¹; Hideo Yasunaga².
- 8 **Affiliations**: ¹Division of Cardiology, Osaka General Medical Center, Osaka, Japan. ²Department of
- 9 Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo,
- 10 Tokyo, Japan. ³Division of Cardiovascular Intensive Care, Nippon Medical School, Tokyo, Japan.
- ⁴Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan.
- 12 ⁵Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
- ⁶Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo,
- 14 Japan. ⁷Department of Cardiology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
- ⁸Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki,
- 16 Japan.

17

22

23

24

25

1

3

- 18 **Address for correspondence:** Hiroyuki Ohbe
- 19 Department of Clinical Epidemiology and Health Economics, School of Public Health, The
- 20 University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 1130033, Japan
- 21 TEL: +81-3-5841-1887 FAX: +81-3-5841-1888 E-mail: hohbey@gmail.com

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Abstract Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes. Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups. Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, -3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group. Conclusions: This nationwide inpatient database study showed that ECPella was not associated with a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP. **Keywords:** cardiogenic shock; mechanical circulatory support; extracorporeal membrane oxygenation; intra-aortic balloon pumping; heart-assist device

Introduction

3 Venoarterial extracorporeal membrane oxygenation (ECMO) provides strong hemodynamic support

to patients with cardiogenic shock through retrograde aortic blood flow in addition to oxygenation;¹

however, even the latest evidence does not support a survival benefit with the routine use of ECMO

in patients with cardiogenic shock.^{2,3} Potential reasons may include bleeding complications,

peripheral vascular ischemia, pulmonary edema, and myocardial ischemia induced by an increased

left ventricular (LV) afterload due to a strong retrograde aortic blood flow.

Previous studies have suggested that LV unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with ECMO is associated with a lower mortality. 4-8 Those studies primarily focused on the effectiveness of LV unloading with an IABP or Impella, using patients who received ECMO alone as controls. The IABP reduces the LV afterload and provides indirect LV unloading through a negative systolic pressure in the descending aorta, 9 whereas the Impella can directly decrease the LV overload and restore the pulmonary flow in patients with ECMO who present with severe LV dysfunction. 10 No randomized controlled trial compared the outcomes of using the Impella versus IABP in combination with ECMO. A recent meta-analysis of seven small-scale observational studies showed no survival benefit of ECPella as compared to ECMO+IABP; however, those studies had a high heterogeneity and the results of the meta-analysis were underpowered to assess the comparative effectiveness. 11 It remains unclear whether differences in the device characteristics between the IABP and Impella affect the clinical outcomes in patients with ECMO who require LV unloading. Therefore, the present study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on the in-hospital mortality and other clinical outcomes, using a nationwide inpatient database in Japan.

Methods

Design and Ethical statement

2 This was a retrospective cohort study using an inpatient administrative database, and the study

conformed to the RECORD reporting guidelines. 12 This study was conducted in accordance with the

amended Declaration of Helsinki and was approved by the Institutional Review Board of The

University of Tokyo (approval number, 3501-(5); 19 May 2021). Because the data were anonymous,

the Institutional Review Board waived the requirement for informed consent.

Data source

1

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

23

24

25

We used the Japanese Diagnosis Procedure Combination inpatient database, which contained administrative claims data and discharge abstracts from more than 1,500 acute care hospitals and covers approximately 90% of all tertiary emergency hospitals in Japan. ¹³ The database includes the following patient-level data for all hospitalizations: age, sex, diagnoses (main diagnosis, admission-precipitating diagnosis, resource-consuming diagnosis, second-most most resource-consuming diagnosis, comorbidities present at admission, and complications arising after admission) recorded with the International Classification of Diseases, 10th Revision (ICD-10) codes, daily procedures recorded using Japanese medical procedure codes, daily drug administration, and discharge status. ¹³ A previous validation study showed that the specificity of the recorded diagnoses in the database exceeded 96%, the sensitivity of the diagnoses ranged from 50% to 80%, and the specificity and sensitivity of the procedures both exceeded 90%.¹⁴

Study population

We identified all patients who received ECMO during hospitalization from September 28, 2016, to

March 31, 2022. September 28, 2016, was the date when the Impella was approved for

reimbursement under the national health insurance in Japan. We excluded patients aged <18 years

and those who had received neither an Impella nor IABP within 2 days before or after the ECMO

initiation. All patients were followed up until they died or were discharged from the hospital.

Treatment groups

1

2

3

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

- 4 Patients who received an Impella within 2 days before or after the ECMO initiation were defined as
- 5 the ECMO+Impella (ECPella) group. Patients who received IABP within 2 days before or after the
- 6 ECMO initiation were defined as the ECMO+IABP group. Patients who received both an Impella
- and IABP within 2 days before or after the ECMO initiation were assigned to the group with the later
- 8 initiation date of the Impella or IABP, or defined as the ECPella group if the Impella or IABP was
- 9 initiated on the same day.

Outcomes

The primary outcome was in-hospital mortality. The secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications including major bleeding, an ischemic stroke, vascular complications, and renal replacement therapy during hospitalization. Major bleeding was defined as the presence of either intracranial bleeding, intraspinal bleeding, pericardial hematomas, intra-abdominal or retroperitoneal hematomas, intra-articular bleeding, intraocular bleeding, or compartment syndrome, which was in accordance with the International Society of Thrombosis and Haemostasis definition. ¹⁵ Ischemic stroke was defined as the presence of cerebral infarction or transient ischemic attack. Vascular complications were defined as an injury to a blood vessel, noncoronary artery dissection, acquired arteriovenous fistula, acute limb thrombosis, and hemorrhage and/or hematoma following a circulatory system procedure. ¹⁶ Those outcomes are defined by the ICD-10 codes listed in **Supplemental Table S1**.

Covariates

The covariates were the fiscal year upon admission, age, sex, smoking history, body mass index upon

admission, Japan Coma Scale upon admission, ¹⁷ Charlson comorbidity index score, comorbidity of peripheral vascular diseases, physical function measured by the Barthel index score upon admission, ¹⁸ cognitive function before admission, home medical care before admission, place before admission, ambulance use, primary diagnoses upon admission, extracorporeal cardiopulmonary resuscitation (ECPR), interventions (percutaneous coronary intervention, coronary artery bypass grafting, surgical valve procedures, or percutaneous valve procedures) before ECMO initiation, organ failure support on the day of the ECMO initiation other than ECMO and mechanical ventilation, ¹⁹ and hospital characteristics (teaching hospital, tertiary emergency hospital, and annual hospital volume of ECMO). The primary diagnosis upon admission was defined when it appeared as a main diagnosis, admission-precipitating diagnosis, most resource-consuming diagnosis, or second most resource-consuming diagnosis¹³, and is defined by the ICD-10 codes listed in **Supplemental Table S1**. ECPR was defined as receiving chest compressions on the same day of the ECMO initiation.

Statistical analysis

We performed a propensity score-matching analysis to compare the outcomes between the ECPella and ECMO+IABP groups. ²⁰ A multivariable logistic regression model using all the covariates listed in **Table 1** was employed to compute the propensity scores for the patients in the ECPella group. Then, we performed a one-to-one nearest-neighbor matching that randomly selected a patient from the treatment group and subsequently paired that patient with the patient in the control group with the closest propensity score. ²¹ In the present study, each time a patient in the ECPella group was identified, the one-to-one nearest-neighbor matching without replacement was performed for the estimated propensity scores using a caliper width set at 20% of the standard deviation of the propensity scores in the patients in the ECMO+IABP group for the exact same calendar year and month. ²⁰ To assess the performance of the matching, the covariates were compared using

standardized differences, with absolute standardized differences of ≤10% considered to denote negligible imbalances between the two groups.²² After the propensity score matching, the primary and secondary outcomes for the two groups were assessed through a generalized linear model accompanied by cluster-robust standard errors with hospitals as the clusters. Differences and their 95% confidence intervals were calculated with generalized linear models using the identity link function, irrespective of the outcome types. For the 60-day in-hospital mortality, we also generated Kaplan–Meier curves and performed log-rank tests in the matched cohort.

All analyses were performed using STATA/SE 17.0 software (StataCorp). Continuous variables are presented as the mean and standard deviation, and categorical variables are presented as the number and percentage. We considered all reported p-values as two-sided and a p<0.05 as statistically significant.

Sensitivity analysis

We performed two sensitivity analyses. First, we performed an overlap weighting analysis.²³ The overlap weighting analysis emphasized the target population with the most overlap in the observed characteristics between two groups. The differences and their 95% confidence intervals were calculated with weighted generalized linear models to compare the outcomes. Second, patients who received ECPR may have had a substantially different clinical course in terms of post-cardiac arrest syndrome and the prognosis as compared to those with cardiogenic shock who did not receive ECPR. Therefore, we performed sensitivity analyses excluding the patients who received ECPR.

Results

Patient characteristics and outcomes

During the study period, we identified 14,525 eligible patients from 661 hospitals (**Figure 1**). Of those, 603 (4.2%) were identified as the ECPella group, and 13,922 (96%) as the ECMO+IABP

group. Of the overall 661 hospitals, Impella was used in 155 (23%).

Table 1 shows the patient characteristics before and after propensity score matching. In the overall cohort, the mean age was 65 years, and 76% were men. Before the propensity score matching, the patients in the ECPella group tended to be younger, had a poor physical and cognitive function upon admission, were transferred from another hospital, had cardiomyopathy, received blood transfusions and dobutamine, and were admitted to a tertiary emergency hospital with a high annual hospital volume of ECMO. In contrast, the patients in the ECMO+IABP group tended to have poor consciousness, were admitted from home, had a cardiac arrest and ventricular tachycardia or fibrillation, and required ECPR, dopamine, and adrenaline. One-to-one propensity score matching created 603 matched pairs. The distributions of the propensity scores before and after the matching are shown in **Supplementary Figures S1** and **S2**. After the propensity score matching, the patient characteristics were well-balanced between the two groups (**Table 1**).

Table 2 shows the outcomes before and after propensity score matching. The crude in-hospital mortality was 58.9% in the ECPella group and 65.6% in the ECMO+IABP group. After propensity score matching, there was no significant difference in in-hospital mortality between the ECPella and ECMO+IABP groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, -3.9% to 8.5%). A Kaplan–Meier analysis with the log-rank test showed no significant difference in the 60-day in-hospital mortality between the two groups (P value = 0.114) (Figure 2). The length of hospital stay was significantly longer in the ECPella group (mean 42.8 days versus 33.7 days; risk difference, 9.1 days; 95% confidence interval, 2.6 to 15.6 days). The total hospitalization cost was also significantly higher in the ECPella group than in the ECMO+IABP group (12,573,000 yen versus 6,857,000 yen; risk differences, 5,716,000 yen; 95% confidence interval, 4,439,000 yen to 6,993,000 yen). Complications more frequently occurred in the ECPella group than in the ECMO+IABP group, including major bleeding (4.0% versus 2.0%; risk difference, 2.0%; 95% confidence interval, 0.007% to 4.0%), vascular complications (4.1% versus 2.2%; risk

difference, 2.0%; 95% confidence interval, 0.04% to 3.9%), and renal replacement therapy during hospitalization (50.6% versus 41.1%; risk difference, 9.5%; 95% confidence interval, 3.0% to 15.9%). There were no significant differences in the other secondary outcomes including the length of ECMO (mean 3.9 days versus 3.3 days; risk difference, 0.6 days; 95% confidence interval, -0.8 to 2.0 days), and ischemic strokes (4.1% versus 4.1%; risk difference, 0.0%; 95% confidence interval, -2.1% to 2.1%). The results of the sensitivity analyses, using an overlap weighting analysis, showed similar results to those for the main analyses (**Table 3**).

Supplementary Table S2 shows the results of the sensitivity analyses excluding patients who received ECPR. After excluding 6,360 patients (44%) who received ECPR, there was no significant difference in in-hospital mortality between the ECPella and ECMO+IABP groups (57.3% versus 50.9%; risk difference, 6.5%; 95% confidence interval, -0.2% to 13.2%). The results of the secondary outcomes were also consistent with the main analyses.

Discussion

To the best of our knowledge, this nationwide cohort study had the largest number of patients among the studies comparing ECPella versus ECMO+IABP. There was no significant difference in in-hospital mortality between the ECPella and ECMO+IABP groups. Meanwhile, ECPella was significantly associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.

The present study found no survival benefit of ECPella as compared to ECMO+IABP. This was consistent with the results of the previous studies.^{8,11} One of those studies, from the Extracorporeal Life Support Organization registry, showed a considerably higher proportion of Impella use in combination with ECMO (33% versus 4.2%).⁸ The previous study performed a propensity score-matching analysis and concluded ECPella as compared to ECMO+IABP was associated with a similar survival in the 560 matched pairs.⁸ Randomized controlled trials comparing

the LV unloading strategies are certainly needed to reach any conclusions. To investigate the comparative effectiveness of Impella or IABP use in combination with ECMO, future studies may need to consider the following. First, the etiology of cardiogenic shock may be a key issue. Underlying diseases with severe impairment of the LV contractility, such as fulminant myocarditis, could receive a pathophysiological benefit from ECPella as a bridge to recovery;^{24,25} however, the current number of cases could not substantiate this subgroup analysis. Indeed, the present study included only 140/1,206 (11.6%) patients with myocarditis. Second, the relationship between the procedural volume (i.e., learning curves) and outcomes should also be considered. Data are scarce for Impella, but the association between the procedural volume and outcomes has been shown for ECMO. Hence, when involving data early after the approval of the Impella, as in the present study, the survival benefit of ECPella may be underestimated. Finally, early recognition of cardiogenic shock and its stabilization by an appropriate timing of mechanical circulatory support (MCS) device use may be more critical than that in which an MCS device is used. 27,28

In the present study, the total hospitalization cost was approximately 1.8 times higher in the ECPella group than in the ECMO+IABP group. This was partly because the cost of the Impella itself was considerably higher than that of an IABP or ECMO; it was approximately 17 times higher than an IABP and 7 times higher than ECMO, according to the national health reimbursement data in Japan. ²⁹ Moreover, a longer hospital stay and more complications including major bleeding, vascular complications, and renal replacement therapy during hospitalization may have contributed to a higher total hospitalization cost. A recent study, using the nationwide inpatient database in Japan, that included patients who required MCS early after admission also showed higher medical costs for ECPella than ECMO+IABP, potentially due to more frequent blood transfusions, a longer duration of ventilator support, and a longer length of hospital stay. ³⁰ In previous studies focusing on the temporal trends before and after the approval of the Impella, the hospitalization cost in the Impella era was higher than that in the pre-Impella era, especially in hospitals where the Impella was more frequently

used.^{31,32} Unplanned readmissions may be an important quality indicator in patients who received an Impella, with limited previous studies showing a high incidence of a 30-day readmission of more than 10%.³³ Unless the survival benefit and reduction in readmissions for ECPella as compared to ECMO+IABP is confirmed, clinicians should be cautious about the patient selection for Impella use in combination with ECMO for LV unloading.

Our results included some important clinical implications. First, the present study provided no evidence of whether IABP or Impella was better for use in combination with ECMO, and evidence of a longer hospital stay, higher total hospitalization cost, and more complications for ECPella. This suggested that ECPella should be implemented in carefully selected patients. Second, further studies are warranted to investigate the outcomes according to the etiology of the cardiogenic shock, learning curves for Impella use, and readmissions in patients who received the Impella.

The present study had several limitations. First, the decision on whether to use an IABP or Impella was at the individual clinician's discretion due to the nature of the present study using the observational database, which led to confounding by indication. We attempted to control for the measured confounding factors using the propensity score analyses; however, we were unable to control for any possible unmeasured variables, such as the vital signs, laboratory data, or LV function. Second, the present study was unable to identify whether patients initially received IABP or Impella and then ECMO, or whether they initially received ECMO and then IABP or Impella for LV unloading. In addition, we defined 152 patients (40%) who received Impella and IABP in combination with ECMO on the same day as the ECPella group; however, some patients might have been downgraded from Impella to IABP due to Impella-related complications. Therefore, misclassifications may have led to a bias in our study. The order and combination of the MCS devices depended on the changing severity of the cardiogenic shock, suggesting that it would be difficult to accurately categorize those complex processes even if additional information were available during hospitalization. Third, the present study was also unable to identify whether the

patients received an Impella 2.5, Impella CP, or Impella 5.0 in the ECPella group. Fourth, the incidence of complications in the present study was considerably lower than in the previous studies. 8,11 Given that the sensitivity of the diagnosis might have been low in our database, there was a possibility of underreporting complications. Finally, many patients in the present study received vasoactive drugs including dopamine and adrenaline. That might have delayed the MCS initiation and caution should be taken in interpreting our results. **Conclusions** The present study using a nationwide inpatient administrative database showed that ECPella was not associated with any survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications as compared to ECMO+IABP.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Declarations Ethics approval and consent to participate: This study was performed in accordance with the amended Declaration of Helsinki, and the Institutional Review Board of The University of Tokyo approved this study (approval number: 3501-(3); 25 December 2017). Consent for publication: The review board waived the requirement for informed consent because of the anonymous nature of the data. No information describing the individual patients, hospitals, or treating physicians was obtained. Availability of data and materials: The datasets analyzed during the current study are not publicly available owing to contracts with the hospitals providing the data to the database. Competing interests: Drs. Nishimoto and Nakata received lecture fees from Abiomed Japan. All other authors declare that they have no conflict of interest. Funding: This research was funded by grants from the Ministry of Health, Labour and Welfare, Japan, grant numbers 23AA2003 and 22AA2003. Authors' contributions: Yuji Nishimoto: Conceptualization, Software, Formal Investigation, Writing - Original Draft; Hiroyuki Ohbe: Conceptualization, Methodology, Software, Formal analysis, Investigation, Writing - Review and Editing; Jun Nakata: Conceptualization, Methodology, Investigation, Writing - Review and Editing, Supervision; Toru Takiguchi:

Conceptualization, Methodology, Investigation, Writing - Review and Editing, Supervision; Mikio Nakajima: Conceptualization, Investigation, Writing - Review and Editing, Supervision; Yusuke Sasabuchi: Conceptualization, Investigation, Writing - Review and Editing, Supervision; Toshiaki Isogai: Software, Formal analysis, Investigation, Data Curation; Hiroki Matsui: Software, Formal analysis, Investigation, Data Curation; Yukihito Sato: Software, Investigation, Resources, Supervision; Tetsuya Watanabe: Software, Investigation, Resources, Supervision; Takahisa Yamada: Software, Investigation, Resources, Supervision; Masatake Fukunami: Software, Investigation, Resources, Supervision; **Hideo Yasunaga**: Writing - Review and Editing, Supervision. All authors read and approved the final manuscript. Acknowledgments: We would like to express our gratitude to Mr. John Martin for his grammatical assistance.

References

1

2

3

- 5 1. Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI/ACVC expert consensus document on
- 6 percutaneous ventricular assist devices. European Heart Journal Acute Cardiovascular Care.
- 7 2021;10:570–583.
- 8 2. Ostadal P, Rokyta R, Karasek J, et al. Extracorporeal Membrane Oxygenation in the
- 9 Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. *Circulation*.
- 10 2023;147:454–464.
- 11 3. Thiele H, Zeymer U, Akin I, et al. Extracorporeal Life Support in Infarct-Related
- 12 Cardiogenic Shock. *N Engl J Med*. 2023;389:1286–1297.
- 4. Russo JJ, Aleksova N, Pitcher I, et al. Left Ventricular Unloading During Extracorporeal
- 14 Membrane Oxygenation in Patients With Cardiogenic Shock. Journal of the American College of
- 15 *Cardiology*. 2019;73:654–662.
- 16 5. Schrage B, Becher PM, Bernhardt A, et al. Left Ventricular Unloading Is Associated With
- 17 Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal
- 18 Membrane Oxygenation: Results From an International, Multicenter Cohort Study. Circulation.
- 19 2020;142:2095–2106.
- 20 6. Bhatia K, Jain V, Hendrickson MJ, et al. Meta-Analysis Comparing Venoarterial
- 21 Extracorporeal Membrane Oxygenation With or Without Impella in Patients With Cardiogenic
- 22 Shock. *Am J Cardiol*. 2022;181:94–101.
- 7. Thevathasan T, Kenny MA, Krause FJ, et al. Left-ventricular unloading in extracorporeal
- 24 cardiopulmonary resuscitation due to acute myocardial infarction A multicenter study.
- 25 Resuscitation. 2023;186:109775.

- 8. Grandin EW, Nunez JI, Willar B, et al. Mechanical Left Ventricular Unloading in Patients
- 2 Undergoing Venoarterial Extracorporeal Membrane Oxygenation. J Am Coll Cardiol.
- 3 2022;79:1239–1250.
- 4 9. Lüsebrink E, Binzenhöfer L, Kellnar A, et al. Venting during venoarterial extracorporeal
- 5 membrane oxygenation. Clin Res Cardiol. 2023;112:464–505.
- 6 10. Eliet J, Gaudard P, Zeroual N, et al. Effect of Impella During Veno-Arterial Extracorporeal
- 7 Membrane Oxygenation on Pulmonary Artery Flow as Assessed by End-Tidal Carbon Dioxide.
- 8 *ASAIO J.* 2018;64:502–507.
- 9 11. Gandhi KD, Moras EC, Niroula S, et al. Left Ventricular Unloading With Impella Versus
- 10 IABP in Patients With VA-ECMO: A Systematic Review and Meta-Analysis. Am J Cardiol.
- 11 2023;208:53–59.
- 12 12. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
- Observational Routinely-collected health Data (RECORD) statement. *PLoS Med.* 2015;12:e1001885.
- 14 13. Yasunaga H. Real World Data in Japan: Chapter II The Diagnosis Procedure Combination
- 15 Database. *ACE*. 2019;1:76–79.
- 16 14. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of
- 17 diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol.
- 18 2017;27:476–482.
- 19 15. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical
- 20 investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost.
- 21 2010;8:202–204.
- 22 16. Lemor A, Dabbagh MF, Cohen D, et al. Rates and impact of vascular complications in
- 23 mechanical circulatory support. Catheter Cardiovasc Interv. 2022;99:1702–1711.
- 24 17. Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict
- stroke outcome--reintroduction of Japan Coma Scale: a cohort study. *BMJ Open.* 2013;3:e002736.

- 1 18. Mahoney FI, Barthel DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md
- 2 *State Med J.* 1965;14:61–65.
- 3 19. Ohbe H, Yamana H, Matsui H, Yasunaga H. Development and validation of a
- 4 procedure-based organ failure assessment model for patients in the intensive care unit: an
- 5 administrative database study. *Acute Med Surg.* 2021;8:e719.
- 6 20. Rosenbaum PR, Rubin DB. Constructing a Control Group Using Multivariate Matched
- 7 Sampling Methods That Incorporate the Propensity Score. *The American Statistician*. 1985;39:33–
- 8 38.
- 9 21. Austin PC. A critical appraisal of propensity-score matching in the medical literature
- between 1996 and 2003. Stat Med. 2008;27:2037–2049.
- 11 22. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates
- between treatment groups in propensity-score matched samples. *Stat Med.* 2009;28:3083–3107.
- 13 23. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am
- 14 J Epidemiol. 2019;188:250–257.
- 15 24. Tominaga Y, Toda K, Miyagawa S, et al. Total percutaneous biventricular assist device
- implantation for fulminant myocarditis. J Artif Organs. 2021;24:254–257.
- 17 25. Kawamura T, Toda K, Yoshioka D, et al. Less Invasive Left Ventricular Unloading With
- 18 Impella May Improve the Clinical Outcomes of Fulminant Myocarditis. ASAIO J. 2023;69:561–568.
- 19 26. Becher PM, Goßling A, Schrage B, et al. Procedural volume and outcomes in patients
- undergoing VA-ECMO support. Crit Care. 2020;24:291.
- 21 27. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the
- 22 classification of cardiogenic shock: This document was endorsed by the American College of
- 23 Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine
- 24 (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv.
- 25 2019;ccd.28329.

- 1 28. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert
- 2 Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed
- 3 by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP),
- 4 American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute
- 5 Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT),
- 6 Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in
- 7 December 2021. *J Am Coll Cardiol*. 2022;79:933–946.
- 8 29. Nishimoto Y, Inohara T, Kohsaka S, et al. Changing Trends in Mechanical Circulatory
- 9 Support Use and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute
- 10 Coronary Syndrome Complicated With Cardiogenic Shock: Insights From a Nationwide Registry
- in Japan. *J Am Heart Assoc.* 2023;e031838.
- 12 30. Nitta M, Nakano S, Kaneko M, Fushimi K, Hibi K, Shimizu S. In-Hospital Mortality in
- 13 Patients With Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation
- With Concomitant Use of Impella vs. Intra-Aortic Balloon Pump A Retrospective Cohort Study
- Using a Japanese Claims-Based Database. Circ J. 2024, doi: 10.1253/circj.CJ-23-0758.
- 16 31. Amin AP, Spertus JA, Curtis JP, et al. The Evolving Landscape of Impella Use in the
- 17 United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical
- 18 Circulatory Support. Circulation. 2020;141:273–284.
- 19 32. Nishimoto Y, Ohbe H, Matsui H, et al. Trends in Mechanical Circulatory Support Use and
- 20 Outcomes of Patients With Cardiogenic Shock in Japan, 2010 to 2020 (from a Nationwide Inpatient
- 21 Database Study). *Am J Cardiol*. 2023;203:203–211.

- 22 33. Kuchtaruk AA, Sparrow RT, Azzalini L, et al. Unplanned readmissions after Impella
- 23 mechanical circulatory support. *Int J Cardiol*. 2023;379:48–59.

Figure Legends Figure 1. Patient flowchart ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump. **Figure 2.** Kaplan–Meier curves for the 60-day in-hospital mortality ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump.

Table 1. Patient characteristics

	Before matching			After matching			
	ECPella ECMO+IABP		ECPella ECMO+IABP				
	(n = 603)	(n = 13,922)	SMD	(n = 603)	(n = 603)	SMD	
Fiscal year upon admission, n (%)							
2016	0 (0.0)	1,291 (9.3)	-45.2	0 (0.0)	0 (0.0)	0	
2017	16 (2.7)	2,845 (20.4)	-57.9	16 (2.7)	13 (2.2)	3.2	
2018	47 (7.8)	2,826 (20.3)	-36.6	47 (7.8)	49 (8.1)	-1.2	
2019	130 (21.6)	2,516 (18.1)	8.8	130 (21.6)	131 (21.7)	-0.4	
2020	168 (27.9)	2,363 (17.0)	26.3	168 (27.9)	167 (27.7)	0.4	
2021	242 (40.1)	2,081 (14.9)	58.7	242 (40.1)	243 (40.3)	-0.3	
Age, years, mean (SD)	63.1 (14.4)	65.2 (14.1)	-14.8	63.1 (14.4)	63.5 (15.5)	-2.7	
Men, <i>n</i> (%)	461 (76.5)	10,642 (76.4)	0.0	461 (76.5)	461 (76.5)	0	
Smoking history, n (%)							
Nonsmoker	239 (39.6)	5,670 (40.7)	-2.2	239 (39.6)	237 (39.3)	0.7	
Current/past smoker	206 (34.2)	4,914 (35.3)	-2.4	206 (34.2)	208 (34.5)	-0.7	
Unknown	158 (26.2)	3,338 (24.0)	5.1	158 (26.2)	158 (26.2)	0	
Body mass index upon admission, kg/m^2 , n							
(%) <18.5	42 (7.1)	955 (6.1)	4.0	42 (7.1)	27 (6.1)	4.0	
	43 (7.1)	855 (6.1)	4.0	43 (7.1)	37 (6.1)	4.0	
18.5–24.9	314 (52.1)	6,601 (47.4)	9.3	314 (52.1)	336 (55.7)	-7.3	
25.0–29.9	137 (22.7)	3,344 (24.0)	-3.1	137 (22.7)	132 (21.9)	2.0	
≥30.0	46 (7.6)	1,062 (7.6)	0.0	46 (7.6)	39 (6.5)	4.5	
Missing data	63 (10.4)	2,060 (14.8)	-13.1	63 (10.4)	59 (9.8)	2.2	
Japan Coma Scale upon admission, n (%)	210 (21 1)			- 10 (- 1 0)	-0- (4-0)		
0 (alert)	310 (51.4)	6,153 (44.2)	14.5	310 (51.4)	283 (46.9)	9.0	
1–3 (dizzy)	84 (13.9)	1,159 (8.3)	17.9	84 (13.9)	91 (15.1)	-3.3	
10–30 (somnolent) 100–300 (coma)	27 (4.5)	560 (4.0)	2.3	27 (4.5)	25 (4.1)	1.6	
Charlson comorbidity index score, mean (SD)	182 (30.2) 1.1 (1.2)	6,050 (43.5) 1.2 (1.3)	-27.8 -2.4	182 (30.2) 1.1 (1.2)	204 (33.8) 1.3 (1.3)	-7.8 -8.8	
Comorbidity of peripheral vascular diseases, n	1.1 (1.2)	438 (3.1)	-2. 4 -2.9	16 (2.7)	1.5 (1.5)	0	
(%)	10 (2.7)	430 (3.1)	-2.7	10 (2.7)	10 (2.7)	U	
Physical function upon admission, n (%)							
Total/severe dependence (BI 0-60)	409 (67.8)	8,630 (62.0)	12.3	409 (67.8)	402 (66.7)	2.5	
Slight/moderate dependence (BI 61-99)	13 (2.2)	385 (2.8)	-3.9	13 (2.2)	16 (2.7)	-3.2	
Independent (BI $= 100$)	86 (14.3)	2,617 (18.8)	-12.2	86 (14.3)	77 (12.8)	4.4	
Missing	95 (15.8)	2,290 (16.4)	-1.9	95 (15.8)	108 (17.9)	-5.8	
Cognitive function before admission, n (%)							
No dementia	403 (66.8)	10,446 (75.0)	-18.1	403 (66.8)	398 (66.0)	1.8	
Mild dementia	31 (5.1)	770 (5.5)	-1.7	31 (5.1)	33 (5.5)	-1.5	
Moderate/severe dementia	21 (3.5)	469 (3.4)	0.6	21 (3.5)	29 (4.8)	-6.7	
Missing	148 (24.5)	2,237 (16.1)	21.2	148 (24.5)	143 (23.7)	1.9	
Home medical care before admission, n (%)	5 (0.8)	172 (1.2)	-4.0	5 (0.8)	10 (1.7)	-7.5	
Place before admission, n (%)							
Home	473 (78.4)	12,736 (91.5)	-37.1	473 (78.4)	493 (81.8)	-8.3	

It is made availe Other hospitals	able under a CC- 124 (20.6)	BY-NC-ND 4.0 Inter 1,081 (7.8)	rnational lid 37.3	cense . 124 (20.6)	99 (16.4)	10.7
Nursing home	6 (1.0)	105 (0.8)	2.6	6 (1.0)	11 (1.8)	-7.0
Ambulance use, n (%)	474 (78.6)	10,512 (75.5)	7.4	474 (78.6)	487 (80.8)	-5.4
Primary diagnosis, n (%)						
Acute coronary syndrome	335 (55.6)	7,846 (56.4)	-1.6	335 (55.6)	341 (56.6)	-2.0
Cardiac arrest	94 (15.6)	3,570 (25.6)	-25.0	94 (15.6)	115 (19.1)	-9.2
Ventricular tachycardia or fibrillation	50 (8.3)	1,586 (11.4)	-10.4	50 (8.3)	49 (8.1)	0.6
Heart failure	85 (14.1)	1,545 (11.1)	9.0	85 (14.1)	93 (15.4)	-3.7
Valve disease	27 (4.5)	761 (5.5)	-4.5	27 (4.5)	22 (3.6)	4.2
Myocarditis	74 (12.3)	629 (4.5)	28.2	74 (12.3)	74 (12.3)	0
Cardiomyopathy	46 (7.6)	495 (3.6)	17.8	46 (7.6)	44 (7.3)	1.3
Aortic disease	13 (2.2)	193 (1.4)	5.8	13 (2.2)	10 (1.7)	3.6
Extracorporeal cardiopulmonary resuscitation,	139 (23.1)	6,221 (44.7)	-46.9	139 (23.1)	140 (23.2)	-0.4
n (%) Interventions before ECMO, n (%)						
Percutaneous coronary intervention	306 (50.7)	7,616 (54.7)	-7.9	306 (50.7)	313 (51.9)	-2.3
Coronary artery bypass grafting	34 (5.6)	804 (5.8)	-0.6	34 (5.6)	39 (6.5)	-3.5
Surgical valve procedures	22 (3.6)	439 (3.2)	2.7	22 (3.6)	17 (2.8)	4.7
Percutaneous valve procedures	4 (0.7)	219 (1.6)	-8.7	4 (0.7)	3 (0.5)	2.2
Organ failure supports on ECMO initiation, n (%)						
Red blood cell transfusion	449 (74.5)	8,647 (62.1)	26.8	449 (74.5)	443 (73.5)	2.3
Fresh frozen plasma transfusion	349 (57.9)	6,634 (47.7)	20.6	349 (57.9)	354 (58.7)	-1.7
Platelet transfusion	147 (24.4)	2,175 (15.6)	22.0	147 (24.4)	134 (22.2)	5.1
Dopamine	123 (20.4)	4,701 (33.8)	-30.4	123 (20.4)	117 (19.4)	2.5
Dobutamine	313 (51.9)	6,191 (44.5)	14.9	313 (51.9)	299 (49.6)	4.6
Noradrenaline	467 (77.4)	10,654 (76.5)	2.2	467 (77.4)	462 (76.6)	2.0
Adrenaline	314 (52.1)	9,802 (70.4)	-38.3	314 (52.1)	308 (51.1)	2.0
Vasopressin	39 (6.5)	982 (7.1)	-2.3	39 (6.5)	43 (7.1)	-2.6
Renal replacement therapy	124 (20.6)	2,596 (18.6)	4.8	124 (20.6)	121 (20.1)	1.2
Hospital characteristics						
Teaching hospital, n (%)	594 (98.5)	13,676 (98.2)	2.2	594 (98.5)	593 (98.3)	1.3
Tertiary emergency hospital, n (%)	443 (73.5)	8,802 (63.2)	22.2	443 (73.5)	429 (71.1)	5.2
Annual hospital volume of ECMO, mean	69.4 (28.1)	52.5 (30.9)	57.2	69.4 (28.1)	70.1 (33.3)	-2.4

BI, Barthel Index; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation; SMD, standardized mean difference.

(SD)

Table 2. Outcomes before and after propensity score matching

	Before matching		After matching			
	ECPella	ECMO+IABP	ECPella	ECMO+IABP	Risk difference	
	(n = 603)	(n = 13,922)	(n = 603)	(n = 603)	(95% CI)	P value
In-hospital mortality, n (%)	355 (58.9)	9,127 (65.6)	355 (58.9)	341 (56.6)	2.3 (-3.9, 8.5)	0.461
Length of hospital stay, days, mean (SD)	42.8 (60.0)	28.7 (42.8)	42.8 (60.0)	33.7 (42.0)	9.1 (2.6, 15.6)	0.006
Length of ECMO, days, mean (SD)	3.9 (7.5)	2.3 (8.3)	3.9 (7.5)	3.3 (13.3)	0.6 (-0.8, 2.0)	0.418
Total hospitalization cost, $\times 10^3$ yen, mean (SD)	12,573 (10,300)	5,679 (5,315)	12,573 (10,300)	6,857 (7,624)	5,716 (4,439, 6,993)	< 0.001
Complications, <i>n</i> (%)						
Major bleeding	24 (4.0)	277 (2.0)	24 (4.0)	12 (2.0)	2.0 (0.007, 4.0)	0.049
Ischemic stroke	25 (4.1)	451 (3.2)	25 (4.1)	25 (4.1)	0.0 (-2.1, 2.1)	1.000
Vascular complications	25 (4.1)	270 (1.9)	25 (4.1)	13 (2.2)	2.0 (0.04, 3.9)	0.046
Renal replacement therapy during hospitalization	305 (50.6)	5,430 (39.0)	305 (50.6)	248 (41.1)	9.5 (3.0, 15.9)	0.004

CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation.

Table 3. Overlap weighting

After IPTW						
ECPella	ECMO+IABP	Risk difference (95% CI)	P value			
60.1	57.8	2.4 (-2.3, 7.0)	0.324			
41.1 (56.7)	33.9 (48.8)	7.2 (2.1, 12.4)	0.006			
3.8 (7.2)	2.9 (12.2)	0.9 (0.06, 1.8)	0.035			
12,133 (9,472)	6,758 (7,014)	5,375 (4,310, 6,440)	< 0.001			
3.9	2.5	1.5 (-0.2, 3.2)	0.091			
4.1	3.8	0.3 (-1.3, 1.9)	0.709			
4.1	2.4	1.7 (-0.2, 3.5)	0.078			
49.8	40.5	9.3 (4.2, 14.5)	< 0.001			
	ECPella 60.1 41.1 (56.7) 3.8 (7.2) 12,133 (9,472) 3.9 4.1 4.1	ECPella ECMO+IABP 60.1 57.8 41.1 (56.7) 33.9 (48.8) 3.8 (7.2) 2.9 (12.2) 12,133 (9,472) 6,758 (7,014) 3.9 2.5 4.1 3.8 4.1 2.4	ECPella ECMO+IABP Risk difference (95% CI) 60.1 57.8 2.4 (-2.3, 7.0) 41.1 (56.7) 33.9 (48.8) 7.2 (2.1, 12.4) 3.8 (7.2) 2.9 (12.2) 0.9 (0.06, 1.8) 12,133 (9,472) 6,758 (7,014) 5,375 (4,310, 6,440) 3.9 2.5 1.5 (-0.2, 3.2) 4.1 3.8 0.3 (-1.3, 1.9) 4.1 2.4 1.7 (-0.2, 3.5)			

CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation.

31,486 patients who received ECMO during hospitalization from September 28, 2016 to March 31, 2022

16,961 patients were excluded:

977 patients under 18 years old

15,984 patients who had received neither Impella nor IABP within 2 days before or after the ECMO initiation

14,525 patients remained

603 patients in the ECPella group

603 patients matched

13,922 patients in the ECMO+IABP group

603 patients matched

